+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Nuclear Medicine Market By Therapy (Radioactive Iodine, Radioactive Antibodies, Others), By Type (SPECT, PET, Alpha-emitters, Beta-emitters, Brachytherapy), By Application, By Therapeutics, By Route of Administration, By End-User, By Region, Forecast & Opportunities, 2025

  • ID: 5022635
  • Report
  • May 2020
  • Region: Global
  • 110 pages
  • TechSci Research
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Nuclear Medicine Market is Estimated to Grow at an Impressive Rate During the Forecast Period.

FEATURED COMPANIES

  • Bracco
  • Eckert & Ziegler
  • IBA Group
  • Lantheus
  • NTP Radioisotopes
  • Roche
  • MORE
The Global Nuclear Medicine Market is estimated to grow at an impressive rate during the forecast period owing to increasing incidence and prevalence of diseases like cancer, initiatives to reduce the demand and supply gap of Mo-99 and increasing research and development activities in radiotherapy to treat various diseases. Furthermore, nuclear medicines are extensively being used in molecular imaging, which is a technique involving molecules as biomarkers for specific molecular processes that determines the onset or progress of a disease.

Nuclear medicines are convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Due to this major factor, chemotherapy methods are being replaced by radiopharmaceuticals or nuclear medicines for cancer treatment. They are also used in applications such as lymphoma and bone metastasis. Some of the nuclear medicines used in diagnostic procedures are F-18, Tc-99, Ga-67, and I-123 while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures. These factors are anticipated to drive the Global Nuclear Medicine Market until 2025.

Apart from above mentioned growth factors, the Global Nuclear Medicine Market also faces some restrains. Short half-life of nuclear medicines or radiopharmaceuticals reduces their potential adoption. Other restraining factors include supply shortages, logistical difficulties, and limited number of trained medical personnel.

The Global Nuclear Medicine Market is segmented based on therapy, type, application, therapeutics, route of administration, end-user and region. Based on application, the Global Nuclear Medicine Market is segmented into cardiology, respiratory, orthopaedics, neurology, oncology and urology. Among them, the oncology segment accounts for the major market share due to increasing prevalence of cancer worldwide. Based on type, the nuclear medicine market is segmented into SPECT, PET, alpha-emitters, beta-emitters and brachytherapy. The SPECT segment accounts for the largest market share and is expected to hold its dominance in the coming years owing to low cost and wide usage in different applications.

Major players operating in the Global Nuclear Medicine Market include Cardinal Health, Curium, Lantheus, Bracco, Advanced Accelerator Applications, NTP Radioisotopes, Eckert & Ziegler, Jubilant DraxImage, GE Healthcare, Siemens Healthineers, Rotem Industries, Eczacibasi-Monrol, IBA Group, Ire-Elit, Lucerno Dynamics, Positron Corporation, NorthStar Medical Radioisotopes, Pharmalucence, Norgine, Roche and others. Key market players are implementing activities like product developments, business expansion, and collaborative development to maintain significant share in the market for nuclear medicine.

Years considered for this report:
  • Historical Years: 2015-2018
  • Base Year: 2019
  • Estimated Year: 2020
  • Forecast Period: 2021–2025
Objective of the Study:
  • To analyze and forecast the market size of the Global Nuclear Medicine Market.
  • To classify and forecast the Global Nuclear Medicine Market based on therapy, type, application, therapeutics, route of administration, end-user, company and regional distribution.
  • To identify drivers and challenges for the Global Nuclear Medicine Market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Nuclear Medicine Market.
  • To conduct pricing analysis for the Global Nuclear Medicine Market.
  • To identify and analyze the profile of leading players operating in the Global Nuclear Medicine Market.
The author performed both primary as well as exhaustive secondary research for this study. Initially, researchers sourced a list of manufacturers across the globe. Subsequently, researchers conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, researchers could include the manufacturers which could not be identified due to the limitations of secondary research. The author analyzed the manufacturers, distribution channels and presence of all major players across the globe.

The author calculated the market size of the Global Nuclear Medicine Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. Researchers sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:
  • Nuclear medicine manufacturer, suppliers, distributors and other stakeholders
  • Hospitals & Clinics
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to nuclear medicine
  • Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:
In this report, the Global Nuclear Medicine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Therapy:
  • Radioactive Iodine
  • Radioactive Antibodies
  • Radioactive Phosphorus
  • Others
Market, By Type:
  • SPECT (Single Photo Emission Computed Tomography)
  • PET (Positron Emission Tomography)
  • Alpha-emitters
  • Beta-emitters
  • Brachytherapy
Market, By Application:
  • Cardiology
  • Respiratory
  • Orthopaedics
  • Neurology
  • Oncology
  • Urology
Market, By Therapeutics:
  • Alpha Particle Emitters
  • Beta Particle Emitters
  • Auger Electron Emitters
Market, By Route of Administration:
  • Oral
  • Intravenous
  • Nasal
Market, By End-User:
  • Hospitals
  • Diagnostic Centers
  • Others
Market, By Region:
  • Asia-Pacific
  • Europe
  • North America
  • South America
  • Middle East & Africa
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Nuclear Medicine Market.

Available Customizations:
With the given market data, researchers offers customizations according to a company’s specific needs.

This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. If you buy the ‘Multi-user’ License of this report before June 2020, you will get a free update in form of market data excel sheet within 3 to 6 months of your purchase on request.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bracco
  • Eckert & Ziegler
  • IBA Group
  • Lantheus
  • NTP Radioisotopes
  • Roche
  • MORE
1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Nuclear Medicine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Therapy (Radioactive Iodine, Radioactive Antibodies, Radioactive Phosphorus, Others
5.2.2. By Type (SPECT (Single photo emission computed tomography), PET (Positron emission tomography), Alpha-emitters, Beta-emitters, Brachytherapy)
5.2.3. By Application (Cardiology, Respiratory, Orthopaedics, Neurology, Oncology, Urology)
5.2.4. By Therapeutics (Alpha Particle Emitters, Beta Particle Emitters, Auger Electron Emitters)
5.2.5. By Route of Administration (Oral, Intravenous, Nasal)
5.2.6. By End-User (Hospitals, Diagnostic centers, Others)
5.2.7. By Company (2019)
5.2.8. By Region
5.3. Market Attractiveness Index

6. Asia-Pacific Nuclear Medicine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Therapy
6.2.2. By Type
6.2.3. By Application
6.2.4. By Therapeutics
6.2.5. By Route of Administration
6.2.6. By End-User
6.2.7. By Country
6.3. Market Attractiveness Index
6.4. Asia-Pacific: Country Analysis
6.4.1. China Nuclear Medicine Market Outlook
6.4.1.1. Market Size & Forecast
6.4.1.1.1. By Value
6.4.1.2. Market Share & Forecast
6.4.1.2.1. By Therapy
6.4.1.2.2. By Type
6.4.1.2.3. By Application
6.4.1.2.4. By Therapeutics
6.4.1.2.5. By Route of Administration
6.4.1.2.6. By End-User
6.4.2. India Nuclear Medicine Market Outlook
6.4.2.1. Market Size & Forecast
6.4.2.1.1. By Value
6.4.2.2. Market Share & Forecast
6.4.2.2.1. By Therapy
6.4.2.2.2. By Type
6.4.2.2.3. By Application
6.4.2.2.4. By Therapeutics
6.4.2.2.5. By Route of Administration
6.4.2.2.6. By End-User
6.4.3. Japan Nuclear Medicine Market Outlook
6.4.3.1. Market Size & Forecast
6.4.3.1.1. By Value
6.4.3.2. Market Share & Forecast
6.4.3.2.1. By Therapy
6.4.3.2.2. By Type
6.4.3.2.3. By Application
6.4.3.2.4. By Therapeutics
6.4.3.2.5. By Route of Administration
6.4.3.2.6. By End-User
6.4.4. South Korea Nuclear Medicine Market Outlook
6.4.4.1. Market Size & Forecast
6.4.4.1.1. By Value
6.4.4.2. Market Share & Forecast
6.4.4.2.1. By Therapy
6.4.4.2.2. By Type
6.4.4.2.3. By Application
6.4.4.2.4. By Therapeutics
6.4.4.2.5. By Route of Administration
6.4.4.2.6. By End-User
6.4.5. Singapore Nuclear Medicine Market Outlook
6.4.5.1. Market Size & Forecast
6.4.5.1.1. By Value
6.4.5.2. Market Share & Forecast
6.4.5.2.1. By Therapy
6.4.5.2.2. By Type
6.4.5.2.3. By Application
6.4.5.2.4. By Therapeutics
6.4.5.2.5. By Route of Administration
6.4.5.2.6. By End-User
6.4.6. Australia Nuclear Medicine Market Outlook
6.4.6.1. Market Size & Forecast
6.4.6.1.1. By Value
6.4.6.2. Market Share & Forecast
6.4.6.2.1. By Therapy
6.4.6.2.2. By Type
6.4.6.2.3. By Application
6.4.6.2.4. By Therapeutics
6.4.6.2.5. By Route of Administration
6.4.6.2.6. By End-User

7. Europe Nuclear Medicine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Therapy
7.2.2. By Type
7.2.3. By Application
7.2.4. By Therapeutics
7.2.5. By Route of Administration
7.2.6. By End-User
7.2.7. By Country
7.3. Market Attractiveness Index
7.4. Europe: Country Analysis
7.4.1. France Nuclear Medicine Market Outlook
7.4.1.1. Market Size & Forecast
7.4.1.1.1. By Value
7.4.1.2. Market Share & Forecast
7.4.1.2.1. By Therapy
7.4.1.2.2. By Type
7.4.1.2.3. By Application
7.4.1.2.4. By Therapeutics
7.4.1.2.5. By Route of Administration
7.4.1.2.6. By End-User
7.4.2. Germany Nuclear Medicine Market Outlook
7.4.2.1. Market Size & Forecast
7.4.2.1.1. By Value
7.4.2.2. Market Share & Forecast
7.4.2.2.1. By Therapy
7.4.2.2.2. By Type
7.4.2.2.3. By Application
7.4.2.2.4. By Therapeutics
7.4.2.2.5. By Route of Administration
7.4.2.2.6. By End-User
7.4.3. United Kingdom Nuclear Medicine Market Outlook
7.4.3.1. Market Size & Forecast
7.4.3.1.1. By Value
7.4.3.2. Market Share & Forecast
7.4.3.2.1. By Therapy
7.4.3.2.2. By Type
7.4.3.2.3. By Application
7.4.3.2.4. By Therapeutics
7.4.3.2.5. By Route of Administration
7.4.3.2.6. By End-User
7.4.4. Italy Nuclear Medicine Market Outlook
7.4.4.1. Market Size & Forecast
7.4.4.1.1. By Value
7.4.4.2. Market Share & Forecast
7.4.4.2.1. By Therapy
7.4.4.2.2. By Type
7.4.4.2.3. By Application
7.4.4.2.4. By Therapeutics
7.4.4.2.5. By Route of Administration
7.4.4.2.6. By End-User
7.4.5. Russia Nuclear Medicine Market Outlook
7.4.5.1. Market Size & Forecast
7.4.5.1.1. By Value
7.4.5.2. Market Share & Forecast
7.4.5.2.1. By Therapy
7.4.5.2.2. By Type
7.4.5.2.3. By Application
7.4.5.2.4. By Therapeutics
7.4.5.2.5. By Route of Administration
7.4.5.2.6. By End-User
7.4.6. Spain Nuclear Medicine Market Outlook
7.4.6.1. Market Size & Forecast
7.4.6.1.1. By Value
7.4.6.2. Market Share & Forecast
7.4.6.2.1. By Therapy
7.4.6.2.2. By Type
7.4.6.2.3. By Application
7.4.6.2.4. By Therapeutics
7.4.6.2.5. By Route of Administration
7.4.6.2.6. By End-User

8. North America Nuclear Medicine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Type
8.2.3. By Application
8.2.4. By Therapeutics
8.2.5. By Route of Administration
8.2.6. By End-User
8.2.7. By Country
8.3. Market Attractiveness Index
8.4. North America: Country Analysis
8.4.1. United States Nuclear Medicine Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Therapy
8.4.1.2.2. By Type
8.4.1.2.3. By Application
8.4.1.2.4. By Therapeutics
8.4.1.2.5. By Route of Administration
8.4.1.2.6. By End-User
8.4.2. Mexico Nuclear Medicine Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Therapy
8.4.2.2.2. By Type
8.4.2.2.3. By Application
8.4.2.2.4. By Therapeutics
8.4.2.2.5. By Route of Administration
8.4.2.2.6. By End-User
8.4.3. Canada Nuclear Medicine Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Therapy
8.4.3.2.2. By Type
8.4.3.2.3. By Application
8.4.3.2.4. By Therapeutics
8.4.3.2.5. By Route of Administration
8.4.3.2.6. By End-User

9. South America Nuclear Medicine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Therapy
9.2.2. By Type
9.2.3. By Application
9.2.4. By Therapeutics
9.2.5. By Route of Administration
9.2.6. By End-User
9.2.7. By Country
9.3. Market Attractiveness Index
9.4. South America: Country Analysis
9.4.1. Brazil Nuclear Medicine Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Therapy
9.4.1.2.2. By Type
9.4.1.2.3. By Application
9.4.1.2.4. By Therapeutics
9.4.1.2.5. By Route of Administration
9.4.1.2.6. By End-User
9.4.2. Argentina Nuclear Medicine Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Therapy
9.4.2.2.2. By Type
9.4.2.2.3. By Application
9.4.2.2.4. By Therapeutics
9.4.2.2.5. By Route of Administration
9.4.2.2.6. By End-User
9.4.3. Colombia Nuclear Medicine Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Therapy
9.4.3.2.2. By Type
9.4.3.2.3. By Application
9.4.3.2.4. By Therapeutics
9.4.3.2.5. By Route of Administration
9.4.3.2.6. By End-User

10. Middle East and Africa Nuclear Medicine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Type
10.2.3. By Application
10.2.4. By Therapeutics
10.2.5. By Route of Administration
10.2.6. By End-User
10.2.7. By Country
10.3. Market Attractiveness Index
10.4. MEA: Country Analysis
10.4.1. South Africa Nuclear Medicine Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Therapy
10.4.1.2.2. By Type
10.4.1.2.3. By Application
10.4.1.2.4. By Therapeutics
10.4.1.2.5. By Route of Administration
10.4.1.2.6. By End-User
10.4.2. Saudi Arabia Nuclear Medicine Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Therapy
10.4.2.2.2. By Type
10.4.2.2.3. By Application
10.4.2.2.4. By Therapeutics
10.4.2.2.5. By Route of Administration
10.4.2.2.6. By End-User
10.4.3. UAE Nuclear Medicine Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Therapy
10.4.3.2.2. By Type
10.4.3.2.3. By Application
10.4.3.2.4. By Therapeutics
10.4.3.2.5. By Route of Administration
10.4.3.2.6. By End-User

11. Market Dynamics
11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape
13.1. Competition Outlook
13.2. Players Profiled (Leading Companies)
13.2.1. Cardinal Health
13.2.2. Curium
13.2.3. Lantheus
13.2.4. Bracco
13.2.5. Advanced Accelerator Applications
13.2.6. NTP Radioisotopes
13.2.7. Eckert & Ziegler
13.2.8. Jubilant DraxImage
13.2.9. GE Healthcare
13.2.10. Siemens Healthineers
13.2.11. Rotem Industries
13.2.12. Eczacibasi-Monrol
13.2.13. IBA Group
13.2.14. Ire-Elit
13.2.15. Lucerno Dynamics
13.2.16. Positron Corporation
13.2.17. NorthStar Medical Radioisotopes
13.2.18. Pharmalucence
13.2.19. Norgine
13.2.20. Roche

14. Strategic Recommendations

15. About Us & Disclaimer
Note: Product cover images may vary from those shown
3 of 3
  • Cardinal Health
  • Curium
  • Lantheus
  • Bracco
  • Advanced Accelerator Applications
  • NTP Radioisotopes
  • Eckert & Ziegler
  • Jubilant DraxImage
  • GE Healthcare
  • Siemens Healthineers
  • Rotem Industries
  • Eczacibasi-Monrol
  • IBA Group
  • Ire-Elit
  • Lucerno Dynamics
  • Positron Corporation
  • NorthStar Medical Radioisotopes
  • Pharmalucence
  • Norgine
  • Roche
Note: Product cover images may vary from those shown
Adroll
adroll